We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
21 April 1926 to 8 September 2022
Updated 19 April 2022
© Crown copyright 2022
This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit nationalarchives.gov.uk/doc/open-government-licence/version/3 or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: [email protected].
Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.
This publication is available at https://www.gov.uk/government/publications/nhs-screening-programmes-annual-report/nhs-screening-programmes-in-england-2018-to-2019
This data report covers the screening year from 1 April 2018 to 31 March 2019. During this period:
*The 15 newborn conditions screened for were:
†There is no routine screening for babies for beta thalassaemia major, but most cases are detected and reported during newborn screening.
AAA screening is offered to men when they turn 65 (cohort). Men aged 65 and over are most at risk of AAAs, and screening can help spot a swelling in the aorta at an early stage. Men aged over 65 who have not had AAA screening can contact their local service to arrange a test (self-referrals).
Data source: AAA SMaRT
Data extracted: 9 July 2019
Bowel cancer screening is offered to men and women aged 60 to 74 (cohort), every 2 years. People over the invitation age range are not invited, but can request screening every 2 years (self refer). Bowel cancer screening looks for polyps and early stage cancer. Removing polyps reduces the risk of bowel cancer developing.
Note that this data relates to screening using the guaiac faecal occult blood test (gFOBt).[footnote 2]
This data relates to the invited population only. Episodes which originate from requests for screening or attendance at programme surveillance tests are excluded.
Data source: Bowel Cancer Screening System (BCSS), using the reporting tool OBIEE.
Data extracted: 19 November 2019.
Breast screening is offered to women between the ages of 50 up to their 71st birthday (cohort), every 3 years. Women over the invitation age range are not invited, but can request screening every 3 years by contacting their local screening service (self refer). Breast screening detects cancers at an early stage, when effective treatment is more likely.
NHS Digital is responsible for publishing official statistics for the NHS Breast Screening Programme.
Cervical screening is offered to women from the ages of 25 to 64 (cohort). Women aged 25 to 49 are invited every 3 years, and women aged 50 to 64 are invited every 5 years. Cervical screening detects types of human papillomavirus (HPV) which can cause abnormal cells in the cervix. Removing these abnormal cells can prevent cervical cancer developing.
NHS Digital is responsible for publishing official statistics for the NHS Cervical Screening Programme.
Diabetic eye screening is offered yearly to people aged 12 or over who have diabetes (cohort). Screening detects diabetic retinopathy, which can cause sight loss if left undiagnosed and untreated.
Data source: programme performance reports and quarter 4 quarterly submission.
Data collected: June 2019.
R1 = Background retinopathy, R2 = Pre-proliferative retinopathy, R3A = Active proliferative retinopathy, R3S = stable treated proliferative retinopathy, M0 = No maculopathy, M1= Maculopathy.
Note: quarter 4 data for North East Manchester diabetic eye screening service was not available, so quarter 3 data have been used instead.
Fetal anomaly screening is offered to eligible pregnant women at various points during pregnancy (cohort). The tests are to detect the presence or chance of a range of conditions.
Data source: Down’s syndrome Screening Quality Assurance Support Service (DQASS).
Infectious diseases in pregnancy screening is offered to pregnant women (cohort), to detect HIV, hepatitis B and syphilis. Detection and treatment reduces the chance of passing on an infection to the baby, a partner or other family members.
Data source: maternity services (England).
Newborn and infant physical examination screening is offered for babies at 72 hours, and again between 6 and 8 weeks of age (cohort). The examination looks for problems with the baby’s eyes, heart, hips and testes.
Data source: KPI reports and NIPE SMART. Data should be viewed with caution as there are issues with data quality and completeness. (The data is incomplete as not all post referral outcomes are entered on to the NIPE IT system. Only data for providers using the NIPE IT system are included in this report. The NIPE programme team has published the data for this period to demonstrate a baseline for comparison in the future.)
Newborn blood spot screening is offered for babies up until their first birthday, with the exception of testing for cystic fibrosis which is only offered up until 8 weeks of age (cohort). Screening takes place for 9 conditions (see tables in sections 10.1 to 10.9 below, and data for sickle cell disease in section 12 below). Newborn blood spot screening identifies conditions which can be treated to improve a baby’s health, and can help prevent severe disability or even death.
†Excluding 34 pre-term babies
Data source: Newborn Screening Laboratories and Child Health. Data is a snapshot of the annual data returns. Every attempt has been made to provide the most correct, up to date information. Percentage coverage based on the annual KPI data for England: NB1 – Coverage (CCG responsibility at birth).
Newborn hearing screening is offered to babies ideally within the first 4 to 5 weeks after birth (cohort). The test can be carried out up to the age of 3 months. Screening identifies permanent moderate, severe and profound deafness, and hearing impairment. Early detection enables interventions to improve language, speech and communication skills as the baby develops.
Data source: SMaRT4Hearing (S4H).
Data collected: 29 November 2019.
Sickle cell and thalassaemia screening includes antenatal screening for pregnant women (ideally at 10 weeks’ gestation) and screening for fathers (if the baby’s mother is a genetic carrier). Sickle cell screening via newborn blood spot screening for babies takes place one week after birth (cohort). Antenatal SCT screening means parents can find out if they are carriers of the sickle cell or thalassaemia gene, and may therefore have passed it on to their baby.
There is no routine screening for babies at risk of inheriting thalassaemia major. However, most cases of beta thalassaemia major should be detected during newborn screening, but beta thalassaemia carriers are not.
Data source: see notes in tables above.
Men registered with a GP in England and born between 1 April 1953 and 31 March 1954 and who have not already been treated for an AAA. ↩ ↩2 ↩3
gFOBt is the guaiac faecal occult blood test used in the bowel cancer screening programme. ↩
One invite sent per screening subject episode. A subject can have multiple episodes during their ‘bowel cancer screening lifetime’. Number of people invited does not include requests for screening such as over-age self-referrals, later responders or opt back-in episodes. ↩
Of those invited, the number reaching a definitive gFOBt outcome from potentially multiple gFOB test kits. Subjects can receive and return more than one test kit within an episode. ↩
Of those invited and adequately screened, the number reaching a definitive gFOBt outcome of ‘further tests needed’ from potentially multiple gFOB test kits. People who reach a definitive gFOBt outcome of ‘further tests needed’ are then referred for a colonoscopy fitness assessment. ↩
Percentage of people adequately screened (iii) out of those invited (ii) for gFOBt screening. No adjustment is made for undelivered letters and/or test kits. ↩
Percentage of people with a definitive gFOBt outcome of ‘further tests needed’ (iv) out of those who were adequately screened (iii) via gFOBt screening. Positivity is calculated from the invited (ii) population only. No adjustment is made for undelivered letters and/or test kits. ↩
The episode outcomes presented here are for the invited (ii) population only (for the specified fiscal year). Specifically, those invited (ii) who adequately participated and were found to need further tests (iv), who went on to have a diagnostic test (one or more) within the episode. It is important to note that episode outcomes are calculated from the findings of potentially multiple endoscopic or radiological tests within the episode. A patient can only have one episode outcome per episode. ↩ ↩2 ↩3 ↩4 ↩5
Abnormal findings can be for non-neoplastic diagnosis (such as diverticular disease, haemorrhoids, inflammatory bowel disease), non-adenomatous polyp (such as hyperplastic, inflammatory, Peutz-Jeghers polyp), non-adenomatous polyp and non-neoplastic diagnosis or people who have polyps seen at a radiological test only, so no histological confirmation is possible. ↩
% of women aged 50 to <71 invited within 36 months of previous screening, or previous invitation if did not attend. ↩
Registered female population for ages 25 to 64 minus any women ceased for clinical reasons. ↩
% of eligible women screened adequately within the previous 3.5 years for women aged 25 to 49 and 5.5 years for women aged 50 to 64. ↩
Number of adequate tests minus number of negative samples. ↩
DQASS is the Down’s syndrome Screening Quality Assurance Support Service. Flags are assigned to a dataset of nuchal translucency (NT) and crown rump length (CRL) measurements. Flags indicate bias of the dataset. Green flag: NT bias ≤ 0.10mm. Amber flag: NT bias 0.11mm – 0.40mm. Red flag: NT bias > 0.40mm. Red4 flag: assigned if fewer than 25 paired measurements over 4 cycles. No flag: trainee sonographer has < 25 paired measurements. ↩
Figures based on key performance indicator (KPI) data. Exclusions made where completed data was not submitted for all 4 quarters. ↩ ↩2 ↩3 ↩4 ↩5 ↩6 ↩7 ↩8 ↩9 ↩10
Figures based on annual standards data. Exclusions were made when data was incomplete or missing, not where trusts could not account for their whole cohort. ↩ ↩2 ↩3 ↩4 ↩5 ↩6 ↩7 ↩8 ↩9 ↩10 ↩11
Data source: screening KPI reports. ↩ ↩2 ↩3 ↩4 ↩5 ↩6 ↩7 ↩8 ↩9 ↩10
Data source: NIPE SMART (data should be viewed with caution as there are issues with data quality and completeness). ↩ ↩2 ↩3 ↩4 ↩5 ↩6 ↩7 ↩8
Proportion of eligible babies is likely to be a minor underestimate relative to proportion of those tested but accurate data on number of babies tested was available for 2018 to 2019 from NIPE SMART. ↩ ↩2 ↩3 ↩4
Excludes babies who have not reached 4 weeks post screen or 44 weeks gestational age. ↩ ↩2
Based on KPI data. Exclusions made where completed data was not submitted for all 4 quarters. ↩ ↩2 ↩3
Based on provisional antenatal laboratory data (138 of 145 expected returns). Figures may differ to those published in the programme-specific data report for 2018 to 2019. ↩ ↩2 ↩3 ↩4
Based on data submitted by PND laboratories and compiled by the National Congenital Anomaly and Rare Disease Registration Service (NCARDRS). ↩ ↩2
Based on provisional newborn laboratory data. May differ to programme-specific data report for 2018 to 2019. ↩ ↩2 ↩3 ↩4
Screen positive results include babies identified with FS, FSC, FS-other and FE. ↩
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. We’ll send you a link to a feedback form. It will take only 2 minutes to fill in. Don’t worry we won’t send you spam or share your email address with anyone.
We use some essential cookies to make this website work.